EMA Authorised: Reblozyl (Luspatercept) — Bristol Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Reblozyl (luspatercept) by Bristol Myers Squibb Pharma EEIG for treating anemia associated with beta-thalassemia and my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Beta-thalassemia
• Myelodysplastic Syndromes

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Status: Authorised. Therapeutic area: Anemia;Myelodysplastic Syndromes;beta-Thalassemia. MAH: Bristol Myers Squibb Pharma EEIG. Decision date: 18/09/2025. Orphan medicine